Toxoplasma gondii serin-protease inhibitor-1: a new adjuvant candidate for asthma therapy

ARIADNA SOTO, IGNACIO FENOY, VANESA SÁNCHEZ, MARÍA ALDIRICO, MATÍAS PERRONE SIBILIA, MARIANO PICCHIO, NADIA ARCÓN, PATRICIO ACOSTA, ; VALENTINA MARTIN; ALEJANDRA GOLDMAN

Congreso; LXIII Annual Meeting of the Argentinean Society for Immunology; 2015

Immunotherapy is an alternative for asthma treatment. Using an experimental asthma model, we have shown that treatment with TgPI-1 plus allergen (PI+OVA) reduced lung eosinophilia and mucus production. Herein, we evaluated whether TgPI-1 treatment alone (PI) improve asthma symptoms. BALB/c mice were ip. sensitized with OVA/Alum and aerosol challenged. Later, they were intranasally treated with PI (PI) or PI+OVA (OPI). Controls included non-sensitized mice treated with PI alone (NPI), and sensitized mice treated with PBS (O) or OVA (OO). One week later, mice were re-challenged. PI and OPI groups showed reduced airway hyperresponsiveness (NPI:2,7±0,2; Ob:3,7±0,5; OOc:5,3±0,5; PId:2,8±0,2; OPIe:2,3±0,2; cmH2O.s/mL±ES,*, p